

Financial Tear Sheet

Corporate Profile

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate, for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions

Stock Information

FCSC (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$2.03
Change (%)	▼ 0.12 (5.58%)
Volume	288,797
52 Week Low	\$1.45
Market Cap	\$19,809,414
Rolling EPS	-0.04
PE Ratio	N/A
Shares Outstanding	9,758,332

Data as of 02/15/19 4:00 p.m. ET



Recent Headlines & Events

02/06/19 - 8:00 a.m.
Fibrocell to Present at 21st Annual BIO CEO & Investor Conference

01/16/19 - 8:00 a.m.
Fibrocell to Present at Phacilitate Leaders World 2019

Date	Title
03/21/19	Alliance for Regenerative Medicine - 7th Annual Cell & Gene Therapy Investor Day Location New York, NY

12/11/18 - 8:01 a.m.
 Fibrocell Receives \$900,000 Investment from EB
 Research Partnership and Epidermolysis Bullosa
 Medical Research Foundation

04/10/19
 through
 04/12/19

**9th Annual World Orphan Drug
 Congress 2019**

Location Oxon Hill, MD

SEC Filings

Filing Date	Form
02/14/19	SC 13G/A
02/14/19	SC 13G/A
02/12/19	EFFECT
02/08/19	SC 13G/A

Corporate Governance

Douglas J. Swirsky	Chairman of the Board
Julian P. Kirk	Director
Marc B. Mazur	Director
John Maslowski	Director
Kelvin D. Moore	Director
Marcus E. Smith	Director
Christine St.Clare	Director

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	31	5.95	36.5	3,399,422
Mutual Fund	10	.35	1.9	179,508
Director and Officer	1	.01	0.0	3,164

*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
Third Security, LLC	1,653,486	17.8	0	12/31/18
Anson Funds Management LP.	679,408	7.3	679,408	05/29/18
Renaissance Technologies LLC	436,641	4.7	68,700	12/31/18
MSD Partners, L.P.	138,592	1.5	160	12/31/18
The Vanguard Group, Inc.	137,329	1.5	11,935	12/31/18
OxFORD Asset Management	91,533	1.0	79,862	12/31/18
Sabby Management, LLC	42,400	0.5	-637,008	12/31/18
Creative Planning, Inc.	40,877	0.4	-4,800	12/31/18
Citadel LLC	29,926	0.3	29,926	12/31/18
Morgan Stanley Wealth Management	27,460	0.3	17,500	12/31/18

Data provided by Nasdaq. Minimum 15 minutes delayed.